“Variants in the MTHFR gene are associated with increased inflammation in humans.”

This study indicates that MTHFR C677T and MTHFR A1298C gene polymorphisms have opposite effect on systemic inflammation. MTHFR 677 variants had significantly higher NLR (Neutrophil-to-lymphocyte ratio) level than MTHFR 677 wild type, while MTHFR 1298 variants showed the opposite effect on systemic inflammation, tending to have lower NLR and PLR (Platelet-to-lymphocyte ratio) levels.

Polymorphisms in the MTHFR gene, especially C677T, have been associated with various diseases, including cardiovascular diseases (CVDs), cancer, inflammatory conditions, diabetes, and vascular disorders. The polymorphism may affect inflammation, which is identified by increased inflammatory markers, such as c-reactive protein (CRP), white blood cell (WBC) count, and amyloid-A.

In women with higher Hcy (homocysteine) serum levels, the inflammation indexes (ESR and CRP), the serum levels of CTX and, as expected, the prevalence of the MTHFR mutation were significantly higher than in women with normal serum Hcy levels. Our results suggest a significant association between Hcy, BMD and inflammation in postmenopausal osteoporosis.

An increase in homocysteine levels caused by MTHFR gene polymorphisms have been studied as possible risk factors for a variety of common conditions. Studies of MTHFR gene variations in people with these disorders have had mixed results, with associations found in some studies but not in others. Therefore, the role that changes in the MTHFR gene play in these disorders remains unclear.

This study indicates that MTHFR C677T and MTHFR A1298C gene polymorphisms have opposite effect on systemic inflammation, and systemic inflammation may contribute to the pathogenesis for diseases associated with MTHFR C667T gene polymorphism. MTHFR 677 variants had significant higher NLR level than MTHFR 677 wild type (3.77 ± 0.26 vs 3.06 ± 0.18, P = .028).

Both genetic and inflammatory factors are suspected in the etiology of multiple sclerosis (MS). The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism has been associated with increased levels of plasma homocysteine. In MS patients, the levels of inflammatory mediators IL-1β, TNFα, and CRP were higher in T/T genotype compared to other genotypes.

This study indicates that MTHFR C677T and MTHFR A1298C gene polymorphisms have opposite effect on systemic inflammation, and systemic inflammation may contribute to the pathogenesis for diseases associated with MTHFR C667T gene polymorphism. MTHFR 677 variants have significantly higher NLR level than MTHFR 677 wild type while MTHFR 1298 variants showed the opposite effect on systemic inflammation.

The MTHFR C677T polymorphism and the serum levels of inflammatory mediators IL-1β, TNFα, and CRP were measured. In patient's group, the levels of all inflammatory mediators were higher in T/T compared to two other genotypes. We concluded that having T allele of C677T in MS might be accompanied with higher levels of serum inflammatory mediators and a vulnerability to earlier age of onset of disease.

An MTHFR gene mutation might seem to explain your symptoms, from chronic fatigue and pain to brain fog, anxiety, major depression, and hormonal imbalances. But a closer look at the research shows that the health impacts of these common gene variants may actually be quite minimal. The symptoms that have been associated with MTHFR gene variations are more likely to be caused by gut imbalances and inflammation.

The MTHFR C677T mutation itself does not directly cause chronic inflammation, but it can lead to hyperhomocysteinemia, which is associated with elevated inflammatory markers. A 2005 study demonstrated that individuals with the TT genotype (homozygous mutant) had significantly higher levels of inflammatory markers compared to those with CC or CT genotypes: C-reactive protein (CRP) was elevated in TT genotype carriers.

Elevated homocysteine is a common consequence of MTHFR mutations due to low folate levels and poor methylation. Studies have shown that high homocysteine can increase inflammatory processes, leading to injury of the intestinal barrier and intestinal permeability. Hyperhomocysteinemia is also known to increase the risk of developing inflammatory bowel disease (IBD).

When homocysteine levels remain elevated, they can contribute to inflammation, damage the lining of blood vessels, and increase the risk of blood clots, leading to a higher risk of heart disease. For individuals with an MTHFR gene mutation, the body's ability to produce methylfolate is compromised, leading to an inefficient conversion of homocysteine and potentially elevated homocysteine levels.

The MTHFR C677T variant, carried by roughly 35-40% of people, reduces enzyme activity by 30-40% in heterozygotes and up to 70% in homozygotes. With reduced methylfolate production, your cells cannot maintain adequate glutathione or properly regulate inflammatory gene expression, so baseline inflammation creeps upward.

Among mutations, the methylenetetrahydrofolate reductase, or the MTHFR gene mutation, is common. A tremendous amount of research has surfaced regarding the MTHFR gene mutation and methylation. The mutation links to a decreased ability to detoxify. It also connects to 60 chronic health conditions, including Hashimoto's and hypothyroidism, blood clots, infertility, cardiovascular disease, Alzheimer's, depression, birth defects, and certain cancers.

Methylation also impacts how the body repairs soft tissue, builds new blood vessels, and regulates inflammation—all critical components in injury recovery. People with MTHFR variants may heal more slowly, experience lingering inflammation, or have chronic pain syndromes like fibromyalgia or costochondritis.

Recent advances in genetic research have shed light on the complex relationship between specific genetic markers and their role in influencing inflammatory responses. While genetic markers like Rs1800795 (IL-6), Rs1800629 (TNF Alpha), and Rs1205 (CRP) are not definitive predictors of disease, they provide valuable insights into a patient's susceptibility to inflammation-related conditions.

The MTHFR C677T polymorphism was shown to be associated with inflammatory diseases, such as psoriasis and inflammatory bowel disease, while both C677T and A1298C variants have been linked to rheumatoid arthritis. The polymorphism may affect inflammation, which is identified by increased inflammatory markers, such as c-reactive protein (CRP), white blood cell (WBC) count, and amyloid-A.

About 40 percent of people carry at least one MTHFR gene variant that may lead to low levels of folate and other B vitamins and high levels of homocysteine (an amino acid). Over time, the downstream effects of MTHFR mutations can put people at higher risk for many common health problems, such as preventable heart disease, colon cancer, stroke, Alzheimer's disease and other forms of dementia, and more.

There is evidence suggesting a link between MTHFR mutations and IBD, as these mutations may contribute to increased homocysteine levels, leading to oxidative stress and inflammation in the gut. Research suggests an association between MTHFR mutations and MS, as compromised methylation processes due to these mutations may contribute to neuroinflammation and demyelination.